A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 26750243)

Published in Sci Rep on January 11, 2016

Authors

Lin Xia1, Yangfei Xian1, Daning Wang1, Yuanzhi Chen1, Xiaofen Huang1, Xingjian Bi1, Hai Yu1, Zheng Fu1, Xinlin Liu1, Shaowei Li1, Zhiqiang An1,2, Wenxin Luo1, Qinjian Zhao1, Ningshao Xia1

Author Affiliations

1: State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science, Xiamen University; Xiamen 361105, China.
2: Texas Therapeutics Institute, The Brown Foundation of Molecular Medicine, University of Texas Health Science Center at Houston, Houston TX77030, USA.

Articles cited by this

Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72

Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70

ZDOCK: an initial-stage protein-docking algorithm. Proteins (2003) 7.52

Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48

Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol (1993) 3.65

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44

Human papillomavirus infection requires cell surface heparan sulfate. J Virol (2001) 3.32

Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2009) 3.30

Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26

The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem (1999) 3.16

ZRANK: reranking protein docking predictions with an optimized energy function. Proteins (2007) 2.79

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37

ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. Bioinformatics (2014) 2.31

Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77

Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66

Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66

Immunobiology of HPV and HPV vaccines. Gynecol Oncol (2008) 1.66

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology (2006) 1.65

Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60

Accessing the Kabat antibody sequence database by computer. Proteins (1996) 1.54

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine (1995) 1.53

Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52

Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology (2001) 1.52

A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42

Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol (1997) 1.34

A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32

Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27

Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20

ZDOCK predictions for the CAPRI challenge. Proteins (2003) 1.18

Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11

Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine (2012) 1.09

Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16. J Virol (2013) 1.06

Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J (2012) 1.04

Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin (2005) 1.01

Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol (2007) 0.99

A quantitative description of in vitro assembly of human papillomavirus 16 virus-like particles. J Mol Biol (2008) 0.98

Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol (1991) 0.96

Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. Hum Vaccin Immunother (2013) 0.94

The first international standard for antibodies to HPV 16. Vaccine (2011) 0.92

Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog (2014) 0.91

Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol (1995) 0.91

A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. J Virol (2014) 0.88

Homology model and potential virus-capsid binding site of a putative HEV receptor Grp78. J Mol Model (2010) 0.85

Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology (2015) 0.85

The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnol Bioeng (2014) 0.81

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody. PLoS One (2015) 0.81

Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79

Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine (2015) 0.76

Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. Hum Vaccin Immunother (2013) 0.76